Age,years |
57 (53-66) |
56 (52-64) |
57 (55-68) |
0.659 |
Histology
Clear cell
Non-clear cell
|
78 (72.2%)
30 (27.8 %)
|
27(87%)
4 (13%)
|
57 (74%)
20 (26%)
|
0.734
|
Metastatic region sites
1-2
3-4-5
|
88 (81.5%)
20 (18.5%)
|
24 (81.5%)
7 (18.5%)
|
64 (81.5%)
13 (18.5%)
|
0.490
|
Tumor Grade
I
II
III
IV
|
5 (4.6%)
20 (18.6%)
37 (34.3%)
46 (42.5%)
|
3 (4%)
5 (17.8%)
11 (34.7%)
11 (43.6%)
|
2 (2.5%)
15 (19.4%)
26 (33.7%)
35 (45.4%)
|
0.622
|
Treatment type
Pazopanib
Sunitinib
|
64 (59.3%)
44 (40.7%)
|
17 (54.8%)
14 (45.2%)
|
47 (61%)
30 (39%)
|
0.553
|
IMDC risk group
Favorable
Intermediate
Poor
|
9 (8.3%)
66 (61.1%)
33 (30.5%)
|
3 (9.6%)
19 (61.2%)
9 (29%)
|
6 (7.7%)
47 (61%)
24 (31.1%)
|
1
|